Incidental prostate cancer: a 10-year review of a tertiary center, Tehran, Iran

Abstract

ObjectiveIncidental prostate cancer (IPCa) is defined as a symptom-free cancer unexpectedly discovered upon microscopic examination of resected tissue. The aim of this study was to report the correlation between some specific clinical criteria in patients incidentally diagnosed with prostate cancer (PCa) during transurethral resection of the prostate (TURP) or open prostatectomy (OP) after clinically suspected benign prostatic hyperplasia.Patients and methodsThis was a cross-sectional, retrospective study. Data were collected from Shohada-e-Tajrish Hospital database during November 2006 to October 2016. Four hundred and twenty three men suffering from symptomatic benign prostatic hyperplasia who underwent either TURP or OP that provided a prostate specimen were evaluated. The data analysis was performed using Pearson correlation test and independent t-test using SPSS version 20 software.ResultsThe mean age of subjects was 68.74±9.87 years old (45–93 years). The mean prostate specific antigen (PSA) level was 21.47±13.44 ng/mL (0.6–47.1 ng/mL). Results showed that 84 patients (19.9%) had PCa (40 patients who underwent TURP [12.6%] and 44 patients who underwent OP [40.7%] groups). Cut-off point of PSA for detecting IPCa was 3.8 ng/mL in our study, and this showed sensitivity, specificity, negative predictive value, and positive predictive value of 26.08%, 100%, 100%, and 29.79%, respectively. Twenty two patients with cancer had a positive family history for PCa; thus, a significant relationship between familial history of PCa and its occurrence was shown (p=0.0001).ConclusionAccording to the results of this study, the cut-off point for PSA levels in detecting PCa was 3.8 ng/mL, which is similar to that reported by other studies. Familial history of PCa and PSA levels were two predictors in determining the PCa.

Phytochemicals in Prostate Cancer: From Bioactive Molecules to Upcoming Therapeutic Agents

“…Although there is some variation in cancer prevalence, prostate cancer was the most commonly diagnosed cancer in the United States of America (USA), Europe and Oceania in 2012 [9]. In the past decade, much attention has been focused on prostate cancer [10] due to the alarming number of patients and the high mortality rate [11,12]. In fact, prostate cancer is the second most deadly malignancy in men after skin cancer [13].…”

Is Holmium Laser Enucleation of the Prostate a Good Surgical Alternative in Benign Prostatic Hyperplasia Management? A Review Article

“…52 Incidental Prostate Cancer A prostate biopsy is routinely performed to diagnose prostate cancer, but false negative results may be reported. [55][56][57][58] Different from other laser therapy for BPH, HoLEP is a surgical approach which provides a specimen for pathologic examination and therefore final specimen histology might disclose incidental prostate cancer (IPca). Despite preoperative prostate cancer risk assessment with biopsy, up to 13% of patients will be diagnosed with IPca following HoLEP.…”

Chronic pelvic pain syndrome: Highlighting medicinal plants toward biomolecules discovery for upcoming drugs formulation

“…Regarding lab tests, the effectiveness of serum prostate‐specific antigen and semen culture in the evaluation of CPPS remains unclear. If in CPPS cases a statistically significant elevation of serum prostate‐specific antigen was registered, prostate cancer should be evaluated (Abedi, Fallah‐Karkan, Allameh, Ranjbar, & Shadmehr, ; Nadler et al, ), also semen culture is not recommended as a first‐line test of diagnostic consideration (Lee & Choi, ). On the other side, imaging investigations using color Doppler ultrasonography have shown CPPS to be related with increased prostatic blood flow (Cho, Keener, Nghiem, Winter, & Krieger, ).…”